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Statement of Purpose: To compare and correlate maternally reported rates of tobacco use to fetal
cord blood levels of cotinine at the time of delivery. The rationale is to promote awareness of
tobacco use during pregnancy in the tri-state region as discontinuation of smoking is a
modifiable source of prenatal and perinatal morbidity and mortality
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Abstract
The detrimental effects of cigarette use during pregnancy are well documented. Studies have
shown that cigarette smoking while pregnant is associated with multiple adverse outcomes
including pre-term birth, placental abruption, placenta previa, fetal growth restriction, stillbirth,
increased rate of birth defects, and increased risk of sudden infant death syndrome. Cotinine is
the primary metabolite of nicotine and allows for measurement of active as well as passive
exposure. Cotinine freely crosses the placental barrier and maternal concentrations are closely
correlated with newborn plasma levels. The aim of this study was to compare maternally
reported rates of tobacco use to fetal umbilical cord blood cotinine levels at the time of delivery.
A cross-sectional study was conducted on 172 patients. Patients were asked a single yes or no
question in regards to their cigarette use during pregnancy. Cord blood was collected at the time
of delivery and analyzed for serum concentrations of cotinine. Cotinine levels greater than 3.0
ng/mL were considered consistent with the use of tobacco or tobacco cessation products.
Maternal self-reporting of tobacco use indicates a reported tobacco use rate of 27.3% and an
actual use rate of 30.2%. The reported tobacco non-use rate was 72.7% and the actual non-use
rate was 66.3%. The prevalence of tobacco use during pregnancy in our study was 30.2%, while
the overall rate in the United States is reported to be 12.3%. Our findings indicate that selfreported smoking prevalence and verified umbilical cord blood cotinine levels at the time of
delivery have excellent correlation (kappa=0.76). Compared to the national average our study
group also had nearly double the rate of tobacco use. Due to the deleterious effects of cigarette
use during pregnancy continued efforts to educate patients regarding cigarette cessation is of
utmost importance as cessation of tobacco products will improve and promote maternal and fetal
well-being.
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Introduction
The detrimental effects of cigarette use during pregnancy are well documented. Studies have
shown that cigarette smoking is associated with multiple adverse outcomes during pregnancy
including pre-term birth, placental abruption, placenta previa, fetal growth restriction, stillbirth,
increased rate of birth defects, and increased risk of sudden infant death syndrome.1
The adverse effects of cigarette use extend beyond prenatal exposure. Nicotine is associated
with adverse postnatal neurobehavioral, metabolic, cardiovascular, and respiratory outcomes,
sudden infant death syndrome (SIDS) and childhood cancers.2-4 Nicotine is a neurological
stimulant and considered a major contributor to the addictive effect of tobacco products.
Cotinine is the primary metabolite of nicotine and allows for measurement of active as well as
passive exposure. Cotinine freely crosses the placental barrier and maternal concentrations are
strongly correlated with newborn plasma levels.5,6
Overall the rate of reported smoking during pregnancy in the United States has decreased from
18.4% in 1990 to 12.3% in 2010.7,8 However, in the Pregnancy Risk Assessment Monitoring
System, Tong et al reported that West Virginia was one of three states where smoking prevalence

increased between 1990-2010.8 The smoking prevalence in the state of West Virginia is 67%
among adolescents between the age of 13-19 during the last 3 months of pregnancy.9
The aim of this study was to compare and correlate maternally reported rates of tobacco use to
fetal cord blood levels of cotinine at the time of delivery among Appalachian gravidas. An
additional objective was to examine the accuracy of self-reporting for smoking status in pregnant
women. There is a lack of studies examining the frequency of tobacco use in Appalachia. The
health effects of smoking are well recognized but discontinuation of smoking is a modifiable
source of prenatal and perinatal morbidity and mortality. Identifying a higher than the national
average frequency of tobacco usage supports the need to further educate the public regarding the
adverse effects of smoking during pregnancy.
Methods
A cross-sectional study was conducted on 172 patients from April 2013 to February 2014.
Inclusion criteria were consenting patients presenting to the labor and delivery unit at Cabell
Huntington Hospital in active labor or admitted for induction of labor. Exclusion criteria were
patients who delivered precipitously prior to being consented for the study. The study
participants were asked a single yes or no question in regard to cigarette use during pregnancy.
Cord blood was collected at the time of delivery and analyzed for serum concentrations of
cotinine in ng/mL by the Cabell Huntington Hospital laboratory.
For the purpose of this study cotinine levels greater than 3.0 ng/mL were considered consistent
with the use of tobacco or tobacco cessation products.10 A serum cord blood cotinine level of
<3.0 ng/mL would classify a patient as a “non-tobacco user” and cotinine level of >3.0 ng/mL
would classify a patient as a “tobacco user”. Self-reported maternal smoking data was collected
at the time of admission and results were corroborated with cord blood analysis for cotinine.
Demographic information was extracted from the subjects’ electronic medical records.
Approval from the Institutional Review Board at Marshall University was obtained prior to
beginning the study. Statistical analysis for continuous variables was by independent sample ttest using SAS Enterprise Guide 7.1. The project was supported by the Robert C. Byrd Center for
Rural Health, Marshall University, and funding was obtained through the Rural Health Initiative
grant from the West Virginia Higher Education Policy Commission and the Marshall University
School of Medicine Translational Research Pilot Grant program.
Results
The overall prevalence of tobacco products in our study using a cotinine cutoff of >3.0 ng/mL
was 30.2% (Table 1). There were 41 patients who reported tobacco use whose cord cotinine
levels were positive at >3.0 ng/mL and 6 patients who reported tobacco use and cord cotinine
levels were measured <3.0 ng/mL. There were 114 patients who denied tobacco use whose cord
cotinine levels were negative and 11 patients who denied tobacco use while cord cotinine was
>3.0 ng/mL. Comparing maternal reports of tobacco use indicates a reported tobacco use rate of
27.3% and an actual use rate as measured by cotinine in cord blood of 30.2%. The reported
tobacco non-use rate was 72.7% and the actual non-use rate was 66.3%.

Self-reported tobacco use showed excellent agreement with the cotinine levels measured in
umbilical cord blood with a Cohen’s kappa coefficient of 0.76 (0.61-0.80 is excellent
agreement).11 In our study a single yes or no question in regard to maternal tobacco use has a
sensitivity of 79%, specificity of 95%, positive predictive value of 87% and negative predictive
value of 91%.
Table 1: Correlation of maternal self-report and umbilical cord blood cotinine levels
Maternal Self-Report

Cord Cotinine >3.0 ng/mL

Cord Cotinine <3.0 ng/mL Total

Yes

41

6

47

No

11

114

125

Total

52

120

172

Prevalence of tobacco use: 30.2%
Sensitivity 79%
Specificity 95%
Positive Predictive Value 87%
Negative Predictive Value 91%
Kappa = 0.76 (0.61-0.80 is excellent agreement)11
Baseline characteristics were similar among our tobacco non-users and users for maternal age,
BMI, race, urbanization, hemoglobin and hematocrit levels on admission, mode of delivery,
estimated blood loss at the time of delivery, gestational age, hypertension, diabetes, and length of
hospital stay (Table 2). Among the two groups there were no significant differences when
comparing total pregnancies or pregnancy outcomes (term, preterm, abortions, living children).
Maternal tobacco users were noted to be less likely to be married (17.3% vs. 57.5%), more likely
to admit to substance abuse or dependence (26.92% vs. 2.50%), more likely to have Medicaid for
insurance (86.54% vs. 49.17%), and more likely to be unemployed (73.08% vs. 54.17%).
Table 2: Maternal Information. Reported mean + SD for continuous variables or n (%) for
categorical variables. 95% Confidence Interval.

Age
BMI
Cotinine Level (ng/mL)
Race
White
Other
Marital Status
Married
Other

Tobacco Non-User
(cotinine <3 ng/mL)

Tobacco User
(cotinine >3 ng/mL)

p-value

25.92+5.53
32.46+6.53
0.09+.34

25.13+4.15
30.46+7.77
69.65+59.46

0.31
0.08
<.0001

113 (94.17)
7 (5.83)

51 (98.08)
1 (1.92)

69 (57.5)
51 (42.5)

9 (17.31)
43 (82.69)

Self-Reported Substance
Abuse/Dependence
Urbanization
Urban
Rural
Insurance Type
Private
Medicaid
None
Employment
Employed
Not-Employed
Mother Length of Hospital Stay
(days)
Maternal Hypertension
Maternal Diabetes
Maternal Hemoglobin (g/dL)
Maternal Hematocrit (%)
Mode of Delivery
Cesarean Delivery
Vaginal Delivery
Gestational Age at Delivery
(weeks)
Estimated Blood Loss at Time
of Delivery (mL)

3 (2.50)

14 (26.92)

63 (52.5)
57 (47.5)

30 (57.69)
22 (42.31)

57 (47.5)
59 (49.17)
4 (3.33)

5 (9.62)
45 (86.54)
2 (3.85)

55 (45.83)
65 (54.17)
3.76+3.84

14 (26.92)
38 (73.08)
3.40+2.08

0.44

25 (20.83)
12 (10)
11.74+1.22
35.31+3.85

11 (21.15)
4 (7.69)
11.87+1.23
35.84+3.46

0.53
0.39

31 (25.83)
89 (74.17)
38.32+2.08

18 (34.62)
34 (65.38)
38.48+1.91

0.62

395.4+195.4

423.8+229.2

0.41

Fetal outcomes were significantly different in regard to fetal weight, length of neonatal hospital
stay, and neonatal intensive care unit admission (Table 3). Mean weight was 3311+65g in the
non-tobacco users and 3057+60 in the tobacco users (mean+SD), with a p-value of 0.02. This
finding is consistent with previously published literature.1 Hospital length of stay for the infants
was noted to be significantly different, with infants of tobacco non-users staying 5.08+9.62 days
and infants of tobacco users staying 10.65+13.40 (mean+SD), p-value of 0.009. Infants born to
tobacco users were also twice as likely to go to the NICU with 32.69% (n=17) of tobacco users
and only 15.83% (n=19) of non-tobacco users infants being admitted to the unit.
Table 3: Fetal Information. Reported as mean + SD for continuous variables or n (%) for
categorical variables. 95% Confidence Interval.
Gender
Male
Female
1 Minute Apgar
5 Minute Apgar
Birth Weight (grams)

Tobacco Non-User
(cotinine <3 ng/mL)
65 (54.17)
55 (45.83)
8.28+1.20
8.97+0.29
3311+65

Tobacco User
(cotinine >3 ng/mL)
28 (53.85)
24 (46.15)
8.31+0.88
8.85+0.46
3057+60

p-value

0.88
0.08
0.02

Baby Length of Hospital Stay
(days)
Head Circumference (cm)
Fetal Height (cm)
Immediate Post-Partum
Location
Well-Born Nursery
NICU

5.08+9.62

10.65+13.40

0.009

33.99+3.62
165.3+7.17

33.81+1.87
165.6+7.01

0.67
0.80

101 (84.17)
19 (15.83)

35 (67.31)
17 (32.69)

Discussion
West Virginia currently ranks first in United States with 27 of every 100 adults being tobacco
users.12,13 A recent report indicated that 67% of West Virginia pregnant adolescents 19 years of
age or younger smoked during the last 3 months of pregnancy.9 Overall the rate of reported
smoking during pregnancy in the United States is 12.3%.7,8 Our study indicates that smoking
prevalence (based on a cotinine level of >3.0 ng/mL) at the time of delivery among Appalachian
gravidas was 30.2%. These findings indicate that self-reported smoking prevalence and verified
umbilical cord blood cotinine levels at the time of delivery were much higher than the national
average in the United States. Our study is the first to correlate umbilical cord cotinine levels in
babies born in West Virginia with self reported smoking habit of the mothers during pregnancy.
The results of our study are consistent with previous inquires examining self-reported tobacco
use among pregnant women and the correlation with serum concentrations of cotinine. A study
of 448 women using a maternal serum cotinine concentration of >10.0 ng/mL to define tobacco
users determined that 94.9% of women who denied smoking and 87.0% of women who stated
they smoked reported their status accurately (kappa=0.83).14 Kvalvik et al studied a subsample
of 2,997 women in the Norwegian Mother and Child Cohort Study (MoBa) to assess selfreported tobacco use and plasma cotinine concentrations at 18 weeks gestational age using a
cutoff of 12ng/mL.15 The sensitivity and specificity for self-reported smoking was 82% and 99%
respectively. In our study a cotinine level of 3.0 ng/ml or higher was considered positive for
exposure to tobacco usage and this value was based on a previous report by another laboratory.10
This cutoff was adopted for our study as our mothers were of different races and the lower level
will include individuals that occasionally smoke. Cotinine levels resulting from exposure to
second-hand smoke has declined over the past 30 years due to increased smoke free public areas.
Cotinine levels in nonsmokers exposed to second-hand smoke are less than 1 ng/ml;10 it is
unlikely that second-hand smoke exposure was identified as a smoker in our study as our cutoff
level was 3.0 ng/ml.
Intervention strategies to promote cessation of tobacco use, prevent relapse, and avoid
secondhand smoke exposure are essential and should be incorporated during routine prenatal
visits.16 Techniques for intervention range from counseling, cognitive and behavioral therapy,
hypnosis, acupuncture to pharmacologic therapy.17,18 Each method may have a different effect
and outcome, so it is important to individualize the approach for each patient and provide the
risks and benefits that are associated with each option. Smoking cessation prior to 15 weeks
gestation has been shown to provide the greatest benefits for both the fetus and the mother,
however, cessation of smoking at anytime during the pregnancy has shown to be beneficial.19,20

In fact, cessation prior to the third trimester can offer a significant reduction in the low birth
weight that is caused by maternal smoking.20
This study does have limitations. The self-reported daily amount of cigarettes smoked was
obtained however it was not ascertained when the study participants last had a cigarette prior to
presenting to the labor and delivery unit. Perhaps this could be a contributing factor to our
patients who reported using tobacco products but the resultant umbilical cord blood for cotinine
was negative. Another contributing factor could be innate differences in regard to the fetal
metabolism of nicotine and its metabolite cotinine that was measured for this study. Further
studies are needed in the area of fetal metabolism of tobacco products. There was also the
potential for selection bias as all patients who presented to the labor and delivery unit were not
enrolled in the study.
In our study of Appalachian gravidas self-reported smoking prevalence and verified umbilical
cord blood cotinine levels at the time of delivery have excellent correlation. Compared to the
national average our study group also had nearly double the rate of tobacco use. Due to the
deleterious effects of cigarette use during pregnancy continued efforts to educate patients
regarding cigarette cessation is of utmost importance as cessation of tobacco products will
improve and promote maternal and fetal well-being.
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